Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Cash & Equivalents

Cash & Equivalents at other companies

AbbVie logo
AbbVieABBV
$9.39B+81.5%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$78.06M+35.5%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$305.11M+1.4%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$274.5M+35.8%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$667.5M-64.1%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$282.21M+29.6%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
Enterprise value$2.44B+62.3%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's cash & equivalents?
Supernus Pharmaceuticals (SUPN) reported cash & equivalents of $186.32M in Q1 2026.
How has Supernus Pharmaceuticals's cash & equivalents changed year-over-year?
Supernus Pharmaceuticals's cash & equivalents increased by 60.8% year-over-year, from $115.85M to $186.32M.
What is the long-term trend for Supernus Pharmaceuticals's cash & equivalents?
Over 5 years (2020 to 2025), Supernus Pharmaceuticals's cash & equivalents has grown at a -14.8% compound annual growth rate (CAGR), from $288.64M to $129.9M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.